4D MOLECULAR THERAPEUTICS IN (FDMT) Fundamental Analysis & Valuation

NASDAQ:FDMT • US35104E1001

Current stock price

8.98 USD
+0.42 (+4.91%)
At close:
8.98 USD
0 (0%)
Pre-Market:

This FDMT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. FDMT Profitability Analysis

1.1 Basic Checks

  • FDMT had negative earnings in the past year.
  • FDMT had a negative operating cash flow in the past year.
  • In the past 5 years FDMT always reported negative net income.
  • In the past 5 years FDMT always reported negative operating cash flow.
FDMT Yearly Net Income VS EBIT VS OCF VS FCFFDMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -49.34%, FDMT perfoms like the industry average, outperforming 49.52% of the companies in the same industry.
  • With a decent Return On Equity value of -56.69%, FDMT is doing good in the industry, outperforming 60.93% of the companies in the same industry.
Industry RankSector Rank
ROA -49.34%
ROE -56.69%
ROIC N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
FDMT Yearly ROA, ROE, ROICFDMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

  • FDMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FDMT Yearly Profit, Operating, Gross MarginsFDMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. FDMT Health Analysis

2.1 Basic Checks

  • FDMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FDMT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, FDMT has more shares outstanding
  • FDMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FDMT Yearly Shares OutstandingFDMT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
FDMT Yearly Total Debt VS Total AssetsFDMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • FDMT has an Altman-Z score of 1.55. This is a bad value and indicates that FDMT is not financially healthy and even has some risk of bankruptcy.
  • FDMT has a better Altman-Z score (1.55) than 64.41% of its industry peers.
  • There is no outstanding debt for FDMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.55
ROIC/WACCN/A
WACC8.9%
FDMT Yearly LT Debt VS Equity VS FCFFDMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 8.42 indicates that FDMT has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 8.42, FDMT is in the better half of the industry, outperforming 74.47% of the companies in the same industry.
  • FDMT has a Quick Ratio of 8.42. This indicates that FDMT is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 8.42, FDMT is doing good in the industry, outperforming 74.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.42
Quick Ratio 8.42
FDMT Yearly Current Assets VS Current LiabilitesFDMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. FDMT Growth Analysis

3.1 Past

  • FDMT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.51%.
  • FDMT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.42%.
  • The Revenue for FDMT have been decreasing by -64.95% on average. This is quite bad
EPS 1Y (TTM)-32.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.85%
Revenue 1Y (TTM)-99.42%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%2900%

3.2 Future

  • Based on estimates for the next years, FDMT will show a decrease in Earnings Per Share. The EPS will decrease by -6.84% on average per year.
  • Based on estimates for the next years, FDMT will show a very strong growth in Revenue. The Revenue will grow by 141.46% on average per year.
EPS Next Y-25.86%
EPS Next 2Y-9.12%
EPS Next 3Y-5.67%
EPS Next 5Y-6.84%
Revenue Next Year405.19%
Revenue Next 2Y263.72%
Revenue Next 3Y140.6%
Revenue Next 5Y141.46%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FDMT Yearly Revenue VS EstimatesFDMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
FDMT Yearly EPS VS EstimatesFDMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. FDMT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FDMT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FDMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FDMT Price Earnings VS Forward Price EarningsFDMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FDMT Per share dataFDMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • FDMT's earnings are expected to decrease with -5.67% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.12%
EPS Next 3Y-5.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FDMT Dividend Analysis

5.1 Amount

  • No dividends for FDMT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FDMT Fundamentals: All Metrics, Ratios and Statistics

4D MOLECULAR THERAPEUTICS IN

NASDAQ:FDMT (3/19/2026, 8:00:02 PM)

Premarket: 8.98 0 (0%)

8.98

+0.42 (+4.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27
Earnings (Next)05-06
Inst Owners106.1%
Inst Owner Change38.86%
Ins Owners3.54%
Ins Owner Change0.17%
Market Cap458.07M
Revenue(TTM)120.00K
Net Income(TTM)-209.18M
Analysts82.35
Price Target32.9 (266.37%)
Short Float %20.66%
Short Ratio13.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.45%
Min EPS beat(2)-9.71%
Max EPS beat(2)-1.18%
EPS beat(4)1
Avg EPS beat(4)-4.14%
Min EPS beat(4)-9.71%
Max EPS beat(4)2.21%
EPS beat(8)4
Avg EPS beat(8)-0.12%
EPS beat(12)7
Avg EPS beat(12)5.39%
EPS beat(16)10
Avg EPS beat(16)5.21%
Revenue beat(2)0
Avg Revenue beat(2)-82.71%
Min Revenue beat(2)-96.07%
Max Revenue beat(2)-69.35%
Revenue beat(4)0
Avg Revenue beat(4)-90.44%
Min Revenue beat(4)-99.94%
Max Revenue beat(4)-69.35%
Revenue beat(8)1
Avg Revenue beat(8)28.44%
Revenue beat(12)2
Avg Revenue beat(12)14.25%
Revenue beat(16)3
Avg Revenue beat(16)0.78%
PT rev (1m)-2.6%
PT rev (3m)-2.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3817.25
P/FCF N/A
P/OCF N/A
P/B 1.24
P/tB 1.24
EV/EBITDA N/A
EPS(TTM)-3.75
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-3.63
FCFYN/A
OCF(TTM)-3.6
OCFYN/A
SpS0
BVpS7.23
TBVpS7.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.34%
ROE -56.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.44%
Cap/Sales 1295.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.42
Quick Ratio 8.42
Altman-Z 1.55
F-Score2
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)209.37%
Cap/Depr(5y)259.38%
Cap/Sales(3y)3538.16%
Cap/Sales(5y)2134.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.85%
EPS Next Y-25.86%
EPS Next 2Y-9.12%
EPS Next 3Y-5.67%
EPS Next 5Y-6.84%
Revenue 1Y (TTM)-99.42%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%2900%
Revenue Next Year405.19%
Revenue Next 2Y263.72%
Revenue Next 3Y140.6%
Revenue Next 5Y141.46%
EBIT growth 1Y5.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.13%
EBIT Next 3Y-14.19%
EBIT Next 5YN/A
FCF growth 1Y-141.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-150.13%
OCF growth 3YN/A
OCF growth 5YN/A

4D MOLECULAR THERAPEUTICS IN / FDMT Fundamental Analysis FAQ

What is the fundamental rating for FDMT stock?

ChartMill assigns a fundamental rating of 3 / 10 to FDMT.


What is the valuation status of 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?

ChartMill assigns a valuation rating of 0 / 10 to 4D MOLECULAR THERAPEUTICS IN (FDMT). This can be considered as Overvalued.


How profitable is 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?

4D MOLECULAR THERAPEUTICS IN (FDMT) has a profitability rating of 1 / 10.


What is the financial health of 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?

The financial health rating of 4D MOLECULAR THERAPEUTICS IN (FDMT) is 7 / 10.